© 2022 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.